Xeljanz XR Access Update: What Patients Need to Know in 2026

If you've been having trouble filling your Xeljanz XR prescription, you're not alone — and you're not imagining it. While Xeljanz XR is not currently on the FDA's official drug shortage list, patients across the country routinely face delays and roadblocks accessing this once-daily tofacitinib extended-release tablet. Here's a clear, current picture of the access landscape in 2026.

Is Xeljanz XR in Shortage in 2026?

No. As of 2026, Xeljanz XR is not listed as being in active shortage by the FDA. Pfizer continues to manufacture tofacitinib consistently, and there are no supply disruptions affecting the extended-release 11 mg tablets.

However, many patients experience what feels like a shortage because of how specialty medications are distributed and covered. Prior authorization requirements, step therapy policies, specialty pharmacy restrictions, and very high retail prices create very real barriers between patients and their medication.

What's Changed in 2026: Generic Tofacitinib XR Now FDA-Approved

One significant development for patients: the FDA approved a generic version of Xeljanz XR (tofacitinib extended-release) from Ajanta Pharma in August 2025. This is potentially good news for patients who rely on the once-daily extended-release formulation, as generic versions are typically less expensive once they reach market.

However, FDA approval does not guarantee immediate pharmacy availability. Generic drug manufacturers must work through distribution channels, and pharmacies need to stock the product. As of early 2026, the generic Xeljanz XR may still be difficult to find at retail pharmacies. Ask your pharmacist about availability in your area.

Immediate-Release Generic Tofacitinib: Already Available

Generic tofacitinib in the immediate-release form (equivalent to Xeljanz 5 mg tablets) has been available since June 2021. For patients who can tolerate twice-daily dosing, this formulation delivers the same active ingredient as Xeljanz XR and is significantly more affordable. GoodRx prices for generic tofacitinib IR are substantially lower than for brand-name Xeljanz XR.

What Are the Main Access Barriers for Xeljanz XR Patients in 2026?

Here's a breakdown of the most common reasons patients struggle to fill Xeljanz XR:

Prior Authorization (PA): Nearly every insurer requires PA for Xeljanz XR. Processing can take days to weeks.

Step Therapy: Many plans require failure of a TNF blocker before they'll approve a JAK inhibitor.

Specialty Pharmacy Routing: Your local pharmacy may not be allowed to dispense it under your plan.

Insurance Plan Changes: New plan years or employer changes can reset your PA status.

Cost Without Insurance: Retail cash price of ~$8,700/month is prohibitive for uninsured patients.

What Should I Do If I Can't Get My Xeljanz XR?

Contact your prescriber immediately. They can check PA status, submit appeals, or prescribe a bridge supply or alternative.

Call XELSOURCE at 1-844-935-5269. Pfizer's patient support program can help navigate PA and connect you to savings programs.

Check copay savings eligibility. The Pfizer Co-Pay Savings Program can reduce your monthly cost to as little as $0 for commercially insured patients (up to $15,000/year in savings).

Find pharmacies that can fill it. Use medfinder to find which pharmacies near you carry Xeljanz XR and can fill your prescription.

Looking Ahead: What Could Change for Xeljanz XR Patients

As generic tofacitinib XR enters wider distribution in 2026, costs for patients should gradually decrease. More generic competitors in this space typically lead to lower insurance tier placements and lower out-of-pocket costs. Watch for updates from your insurer on whether generic tofacitinib XR is covered on their formulary and at what tier.

For patients who need a different option while navigating access issues, read our guide to alternatives to Xeljanz XR to understand your options.